Remove FDA Approval Remove Pharmacy Remove Trials
article thumbnail

US FDA approves Pfizer’s migraine nasal spray Zavzpret

Pharmaceutical Technology

The company stated that the regulatory approval expands its migraine portfolio, which includes oral therapy for acute and preventive treatment. The regulator granted the approval based on two pivotal placebo-controlled, double-blind, randomised trials. The company expects to launch Zavzpret in pharmacies in July.

article thumbnail

Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea

XTalks

Emrosi’s approval was based on data from a pair of Phase III clinical trials for the treatment of rosacea. The trials met all co-primary and secondary endpoints, with participants having successfully completed the 16-week treatment with no significant safety issues.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The FDA Just Approved The First Fast-Acting Nasal Spray For Migraines

AuroBlog - Aurous Healthcare Clinical Trials blog

The US Food and Drug Administration has approved a fast-acting nasal spray from Pfizer designed to treat migraines, the US pharmaceutical giant said Friday.

article thumbnail

Vanrafia (Atrasentan) Earns FDA Approval for IgAN, Achieved Proteinuria Reduction

XTalks

The FDAs accelerated approval of Vanrafia was based on an interim analysis of the global Phase III ALIGN trial, in which atrasentan added to optimized reninangiotensin system inhibitor therapy achieved a 36.1% reduction in urine proteintocreatinine ratio versus placebo (p<0.0001).

article thumbnail

Acute Leukemia Drug Revuforj Wins FDA Approval, Second Approval for Syndax this Year

XTalks

Syndax Pharmaceuticals’ Revuforj (revumenib) has won US Food and Drug Administration (FDA) approval for the treatment of relapsed or refractory (R/R) acute leukemia in patients aged one year and older who have a lysine methyltransferase 2A ( KMT2A, formerly MLL ) gene translocation. times its initial investment.

article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

Related: Arrowhead Pharmas New Rare Disease Campaign for FCS Highlights Importance of Lowering Triglycerides The FDAs approval of Crenessity was based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic CAH. Crenessity marks the third approved drug for Neurocrine.

Genetics 116
article thumbnail

FDA Approves Dong-A ST’s Imuldosa (Ustekinumab), a Stelara Biosimilar

XTalks

Stelara Price Reductions and Expanding Biosimilar Competition Imuldosa’s approval joins a wave of Stelara biosimilars. In October 2023, Amgen’s Wezlana (ustekinumab-auub) became an interchangeable biosimilar approved by the FDA, eligible for pharmacy-level substitution.